相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
Paul Toren et al.
EUROPEAN UROLOGY (2015)
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Roberta Ferraldeschi et al.
EUROPEAN UROLOGY (2015)
Circulating Tumor Cells: A Multifunctional Biomarker
Timothy A. Yap et al.
CLINICAL CANCER RESEARCH (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
Katri A. Leinonen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing
Ellen Heitzer et al.
CANCER RESEARCH (2013)
Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Christian Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma
Lei Lei Chen et al.
NATURE MEDICINE (2013)
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
Tobias M. Gorges et al.
BMC CANCER (2012)
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Alison H. M. Reid et al.
MODERN PATHOLOGY (2012)
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers
Dena Marrinucci et al.
PHYSICAL BIOLOGY (2012)
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
David T. Miyamoto et al.
CANCER DISCOVERY (2012)
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients
Robert Koenigsberg et al.
ACTA ONCOLOGICA (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan et al.
CLINICAL CANCER RESEARCH (2011)
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood
Stephen D. Mikolajczyk et al.
JOURNAL OF ONCOLOGY (2011)
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
A. H. M. Reid et al.
BRITISH JOURNAL OF CANCER (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2009)
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
Kanishka Sircar et al.
JOURNAL OF PATHOLOGY (2009)
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression
Bo Han et al.
MODERN PATHOLOGY (2009)
Oncogenic Activating Mutations Are Associated with Local Copy Gain
Barmak Modrek et al.
MOLECULAR CANCER RESEARCH (2009)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Brett S. Carver et al.
NATURE GENETICS (2009)
Is PTEN loss associated with clinical outcome measures in human prostate cancer?
P. McCall et al.
BRITISH JOURNAL OF CANCER (2008)
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer
Carol O'Brien et al.
CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Case study of the morphologic variation of circulating tumor cells
Dena Marrinucci et al.
HUMAN PATHOLOGY (2007)
PTEN function in normal and neoplastic growth
Lionel M. L. Chow et al.
CANCER LETTERS (2006)
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias
Maisa Yoshimoto et al.
CANCER GENETICS AND CYTOGENETICS (2006)
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion
PCMS Verhagen et al.
JOURNAL OF PATHOLOGY (2006)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells
HK Lin et al.
MOLECULAR ENDOCRINOLOGY (2004)
Sex steroid hormone receptors in human thymoma
H Ishibashi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
分享论文
